Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTX120 in Relapsed or Refractory Multiple Myeloma
NCT04244656Phase 1Terminated
- Sponsor
- CRISPR Therapeutics
- Start
- Jan 2020
- Primary completion
- Jan 2024
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of CTX120 in multiple myeloma (MM), sponsored by CRISPR Therapeutics. Primary endpoints: Incidence of adverse events at 28 days and Objective Response Rate at 60 months. Started Jan 2020; status: terminated.
02
Drugs
CTX120
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04244656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04244656.